Federal Register of Legislation - Australian Government

Primary content

PB 68 of 2019 Other as made
This instrument amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015).
Administered by: Health
Registered 30 Aug 2019
Tabling HistoryDate
Tabled HR09-Sep-2019
Tabled Senate09-Sep-2019
To be repealed 15 Nov 2019
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

PB 68 of 2019

 

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2019 (No. 8)

 

National Health Act 1953

___________________________________________________________________________

 

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

 

Dated 29 August                                                2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health


 

___________________________________________________________________________

1          Name of Instrument

(1)          This Instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2019 (No. 8).

(2)          This Instrument may also be cited as PB 68 of 2019.

2          Commencement

This Instrument commences on 1 September 2019.

3          Amendment of National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

Schedule 1 amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015).

 


Schedule 1       Amendments

[1]        Schedule 1, after entry for Brivaracetam in the form Tablet 100 mg

insert:

Buprenorphine

Injection (modified release) 8 mg in 0.16 mL pre-filled syringe

20

1

0

 

 

Injection (modified release) 16 mg in 0.32 mL pre-filled syringe

20

1

0

 

 

Injection (modified release) 24 mg in 0.48 mL pre-filled syringe

20

1

0

 

 

Injection (modified release) 32 mg in 0.64 mL pre-filled syringe

20

1

0

 

 

Injection (modified release) 64 mg in 0.18 mL pre-filled syringe

20

1

0

 

 

Injection (modified release) 96 mg in 0.27 mL pre-filled syringe

20

1

0

 

 

Injection (modified release) 128 mg in 0.36 mL pre-filled syringe

20

1

0

 

[2]        Schedule 1, entry for Esomeprazole in the form Capsule (enteric) 20 mg (as magnesium)

insert as first entry:

 

 

20

30

1

 

[3]        Schedule 1, entry for Esomeprazole in the form Capsule (enteric) 40 mg (as magnesium)

insert as first entry:

 

 

20

30

1

 

[4]        Schedule 1, entry for Esomeprazole in the form Tablet (enteric coated) 20 mg (as magnesium trihydrate)

insert as first entry:

 

 

20

30

1

 

[5]        Schedule 1, entry for Esomeprazole in the form Tablet (enteric coated) 40 mg (as magnesium trihydrate)

insert as first entry:

 

 

20

30

1

 

[6]        Schedule 1, omit entry for Hydrochlorothiazide with triamterene

[7]        Schedule 1, entry for Insulin isophane

omit:

 

Injection (bovine) 100 units per mL, 10 mL

20

5

2

 

[8]        Schedule 1, entry for Insulin neutral

omit:

 

Injection (bovine) 100 units per mL, 10 mL

20

5

2

 

[9]        Schedule 1, entry for Lansoprazole in the form Capsule 30 mg

insert as first entry:

 

 

20

28

1

 

[10]      Schedule 1, entry for Lansoprazole in the form Tablet 30 mg (orally disintegrating)

insert as first entry:

 

 

20

28

1

 

[11]      Schedule 1, entry for Omeprazole in the form Capsule 20 mg

insert as first entry:

 

 

20

30

1

 

[12]      Schedule 1, entry for Omeprazole in the form Tablet 20 mg

insert as first entry:

 

 

20

30

1

 

[13]      Schedule 1, entry for Omeprazole in the form Tablet 20 mg (as magnesium)

insert as first entry:

 

 

20

30

1

 

[14]      Schedule 1, entry for Pantoprazole in the form Sachet containing granules 40 mg (as sodium sesquihydrate)

insert as first entry:

 

 

20

30

1

 

[15]      Schedule 1, entry for Pantoprazole in the form Tablet (enteric coated) 40 mg (as sodium sesquihydrate)

insert as first entry:

 

 

20

30

1

 

[16]      Schedule 1, entry for Rabeprazole in the form Tablet containing rabeprazole sodium 20 mg (enteric coated)

insert as first entry:

 

 

20

30

1

 

[17]      Schedule 1, entry for Ribavirin

omit:

 

Tablet 200 mg

20

28

5